Cancer therapy and treatments during COVID-19 era

Giuseppe Montalto, Monica Notarbartolo Di Villarosa, Melchiorre Cervello, Giulia Ramazzotti, Alberto M. Martelli, Manuela Piazzi, Saverio Candido, Stefano Ratti, Kvin Lerpiriyapong, Jorg Basecke, Massimo Libra, William L. Blalock, Shaw M. Akula, Linda S. Steelman, James A. Mccubrey, Lucio Cocco, Giuseppe Montalto, Matilde Y. Follo, Stephen L. Abrams

Risultato della ricerca: Articlepeer review

1 Citazioni (Scopus)

Abstract

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disease progression. This review article will summarize how the treatments of various cancer patients has changed during the COVID-19 era as well as discuss the promise of some existing drugs and other agents to be repurposed to treat this disease.
Lingua originaleEnglish
pagine (da-a)1-11
Numero di pagine11
RivistaAdvances in Biological Regulation
Volume77
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Cancer Research

Cita questo